Prurigo Nodularis is a rare, chronic skin disorder that causes substantial patient burden, but is often overlooked or misdiagnosed and, until recently, had no medications approved by the US Food and Drug Administration. The interprofessional faculty share their real-world perspectives on the diagnosis and treatment of patients with prurigo nodularis to reduce patient burden of disease and improve health outcomes. Highlighting pathophysiologic mechanisms, the faculty discuss the evolving pharmacologic treatment of patients with prurigo nodularis that now includes dupilumab; they also review safety and efficacy data for medications in late-phase clinical investigation. Case studies are discussed to facilitate integration of key concepts into clinical practice.
Course Credit:
1.5 AAPA Category I Hours
1.5 ACPE Contact Hours
1.5 AMA PRA Category 1 CreditsTM
1.5 ANCC Contact Hours
1.5 CA-BRN Contact Hours
1 Pharmacology Hour
Dates:
Opens: 2023-08-31
Closes: 2024-08-31
Target Audience:
Dermatologists, dermatology nurse practitioners and physician associates/assistants, nurses, pharmacists, and other clinicians who may be involved in the management of patients diagnosed with prurigo nodularis, including those in primary care, allergy, immunology, and psychiatry.
This activity is supported by educational grants from Galderma, and Sanofi and Regeneron Pharmaceuticals.
Accreditation
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Annenberg Center for Health Sciences at Eisenhower designates this knowledge-based activity for a maximum of 1.5 hours. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.
Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.5 contact hours, including 1 pharmacology hour.
To receive credit for education contact hours outside of the state of California, please check with your state board of registered nursing for reciprocity.
Additional Content Planners
Tim Drake, PharmD, MBA, BCPS (Medical Writer)No significant relationships to disclose.
Amber Lambert, MSN, FNP-C, DNP (Nurse Planner)
No significant relationships to disclose.
Kam A. Newman, MD (Peer Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES
Associate Professor of Pharmacy Practice
Duquesne University
Pittsburgh, Pennsylvania -
Leigh Ann Pansch, MSN, FNP-BC, DCNP
Dermatologists of Central States
Cincinnati, Ohio -
Jonathan I. Silverberg, MD, PhD, MPH
Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC -
Lindsay C. Strowd, MD
Associate Professor and Interim Chair
Director of Inpatient Consultative Dermatology
Director of Clinical Studies Unit
Department of Dermatology
Director of Developing Initiatives
Office of Academic Affairs
Wake Forest School of Medicine
Winston-Salem, North Carolina -
Najat M. Watch, PA-C
Department of Dermatology
Henry Ford Health System
Dearborn, Michigan
Presenting Faculty
Downloads
Learning Objectives
- Distinguish the unique signs and symptoms of PN in various skin types.
- Recognize the burden of PN on quality of life, including sleep disturbances and psychiatric comorbidities.
- Explain the pathophysiology of PN and the role of IL-4, IL-13, IL-31, and other mediators in itch, inflammation, epithelial dysregulation, and fibrosis.
- Employ evidence-based strategies for treating patients with PN.
- Describe the safety and efficacy of new and emerging treatments for PN.
Faculty Disclosures
Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES
No relationships to disclose.Leigh Ann Pansch, MSN, FNP-BC, DCNP
Consultant: Novartis
Speakers Bureau: AbbVie, Arcutis, Beiersdorf, Dermavant, Eli Lilly, Galderma, Janssen, Regeneron, Sanofi
Jonathan I. Silverberg, MD, PhD, MPH
Advisory Board: Aldena, Biosin, Connect Biopharma
Consultant: AbbVie, Alamar, Aldena, Amgen, AOBiome, Arcutis, Arena, Asana, Aslan, BiomX, Biosion, Bodewell, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, Dermtech, Eli Lilly, Galderma, GlaxoSmithKline, Incyte, Kiniksa, Leo Pharma, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sanofi-Genzyme, Shaperon, TARGET-RWE, Union, UpToDate;
Research Support: Galderma, Incyte, Pfizer
Speaker Bureau: AbbVie, Eli Lilly, Leo Pharma, Pfizer, Regeneron, Sanofi-Genzyme
Stockholder: AbbVie, BioNTech, Eli Lilly, Johnson & Johnson, Moderna, Pfizer, Regeneron
Lindsay C. Strowd, MD
Advisory Board: Incyte
Consultant: Galderma, Regeneron, Sanofi